| |
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
Today’s Big NewsJan 24, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Gabrielle Masson After what many considered a “slow” year for initial public offerings, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal. |
|
|
|
By Kevin Dunleavy Based on a survey of doctors treating patients for pulmonary arterial hypertension, analysts at Leerink Partners believe that Merck’s Winrevair could overcome a slow ramp in 2024 and “have strong uptake growth” in 2025. |
By Nick Paul Taylor Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading. |
By Andrea Park As users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines Agency has embarked on its own metamorphosis from one text-based social media service to the other. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By Fraiser Kansteiner While Fujifilm Diosynth Biotechnologies isn’t immune to the challenges facing the broader CDMO industry, the company’s long-running expansion journey—and its ability to snare high-profile pharma clients—has blunted many of the pressures met by its peers. |
By Conor Hale Intuitive said the limited rollout of its da Vinci 5 system has so far shown strong adoption and contributed to a rise in worldwide procedures. |
By Angus Liu Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. |
By James Waldron The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic biotech Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins the Nasdaq with a $126.4 million offering. |
By Zoey Becker The billionaire family behind former OxyContin maker Purdue Pharma was denied a bankruptcy protection deal in a high-profile Supreme Court ruling last summer. |
By Nick Paul Taylor Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company EDO finding Novo Nordisk’s Ozempic led the pharma field. With Super Bowl LIX approaching, attention is turning to whether the industry will make a rare appearance on the big day. |
By Darren Incorvaia,Zoey Becker Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after landing on Fabrice Chouraqui. Chouraqui was most recently a CEO-partner at Flagship Pioneering and previously served as president of Novartis Pharmaceuticals USA. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
|
|---|
|
|
|
Thursday, February 20, 2025 | 2pm ET / 11am PT Clinical trials only continue to increase in complexity. Join industry experts to explore how AI can transform workflows to help sponsors and CROs better manage data while maintaining speed, quality and compliance. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
